Loading...
Loading...
Analysts at Deutsche Bank initiated coverage on ProQR Therapeutics
PRQR with a Buy rating.
The target price for ProQR Therapeutics is set to $32.
ProQR Therapeutics' shares fell 4% to close at $12.48 yesterday.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in